Adding a new drug, ibrutinib, to usual treatment for brain lymphoma

Official title: Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on September 15, 2026.

The short version

This trial tests if adding a new drug to usual treatment helps people with a type of brain lymphoma.

Read our full plain-language summary

What the trial team says

This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as the care most people get for Primary Central Nervous System Lymphoma (PCNSL).

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number: NCT05998642
Stage of testing: Phase 2
Conditions studied: Non-hodgkin Lymphoma

Where it is running

This trial lists 8 sites.

Alberta
- Arthur J.E. Child Comprehensive Cancer Centre (Calgary)
British Columbia
- BCCA - Vancouver (Vancouver)
Ontario
- Juravinski Cancer Centre at Hamilton Health Sciences (Hamilton)
- Ottawa Hospital Research Institute (Ottawa)
- University Health Network (Toronto)
Quebec
- The Research Institute of the McGill University (Montreal)
- CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) (Québec)
Saskatchewan
- Allan Blair Cancer Centre (Regina)

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.